NYSE:DNA) Ginkgo Bioworks Partners with Universal Cells, an Astellas Company, to Advance Next-Generation iPSC-Derived Cell Therapies for Solid Tumors ...

Q-901 is under clinical development by Qurient and currently in Phase II for Small-Cell Lung Cancer. According to GlobalData, Phase II drugs for Small-Cell Lung Cancer have a 26% phase transition ...

Korean company, top stakeholder of Norwegian firm, silent on closure of US plant Hanwha is facing strong opposition from ...

Pathologic Complete Response reported for 2 patients with cutaneous Squamous Cell CarcinomaMarlborough, Massachusetts--(Newsfile Corp. - January ...

Personalized Medicine : By combining iPSCs with genome-editing technologies like CRISPR, scientists can introduce precise genetic modifications, such as knock-outs, knock-ins, or single base changes, ...

Researchers from the University of Michigan have developed a way of detecting circulating tumor cells in the bloodstream of ...

The Middle East has become a key market for Chinese PV companies, both as a source of demand for hardware and also as a ...

Novel programs will combine validated cell-targeted LNP (ctLNP) delivery with siRNA to selectively modulate T cells in vivoPrograms to focus on ...

Yang Zhang, Ph.D., and Jinjun Shi, Ph.D., both of the Center for Nanomedicine and Department of Anesthesiology, Perioperative ...

Dec. 18, 2024 — Scientists have generated human stem cell models which contain notochord -- a tissue in the developing embryo that acts like a navigation system, directing cells where to build ...

Following the filing of its Quarterly Report on Form 10-Q for the ... or the “Company”), a regenerative medicine company developing placental-derived allogeneic cell therapies and advanced ...